SARS-CoV2 and Hyper-Inflammatory ARDS - The New Kid on the Block

In this third presentation of the five-part Updates on COVID-19 series, Dr. Ivan Rosas, M.D. discusses acute respiratory distress syndrome (ARDS), effective interventions, and ARDS phenotypes. He then relates ARDS research and guidelines to the current coronavirus pandemic and the clinical management of COVID-19. He concludes by introducing COVACTA, a new study focusing on potential pharmacological treatment of patients with severe COVID pneumonia.

CME Information

CME Credit Available

You may claim CME credit after watching this activity.

Needs Statement

Faculty and trainees within the Department of Medicine who are involved in the care of patients need to be regularly updated with the recent advances and guidelines in the fields of internal medicine and quality improvement to increase clinical knowledge, and to implement the advances and guidelines in clinical practice to enhance the quality of patient care and outcomes.

Objectives

At the conclusion of this activity, the participant should be able to:

  • Define phenotypes of adult respiratory distress syndrome (ARDS).
  • Discuss common features of COVID-19 and hyperimmune ARDS.
  • Review ARDS immune modulator clinical trials.
  • Describe a potential role for IL-6 blockade for COVID-19.

Target Audience

  • Physicians
  • Medical Students
  • Fellows
  • Residents

Accreditation/Credit Designation

Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Baylor College of Medicine designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Director

  1. Richard J. Hamill, M.D.

    Richard J. Hamill, M.D.

    Professor
    Baylor College of Medicine

Term of Approval

May 1, 2020 through May 31, 2022. Original release date: May 1, 2020.

Disclosure Policy

The Office of Continuing Medical Education (OCME) makes every effort to develop CME activities that are scientifically based, accurate, current, and objectively presented. In accordance with the Accreditation Council for Continuing Medical Education Standards for Commercial SupportSM, Baylor College of Medicine (BCM) has implemented a mechanism requiring everyone in a position to control the content of an educational activity (e.g., directors, planning committee members, contributors, peer reviewers) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships: 1) at the time of the activity or within 12 months prior; and 2) of their spouses/partners.

Baylor College of Medicine does not view the existence of interests or relationships with commercial entities as implying bias or decreasing the value of a presentation. It is up to the participants to determine whether the interests or relationships influence the presenter with regard to exposition or conclusions.

If at any time during this activity you feel that there has been commercial or promotional bias, please inform us by using the commercial bias comments box in the evaluation form. Please answer the questions about balance in the CME activity evaluation candidly.

Disclosures

The following individual(s) has/have reported financial or other relationship(s) with commercial entities whose products/services may relate to the educational content of this activity:

Presenter

  1. Ivan Rosas, M.D.

    Ivan Rosas, M.D.

    Professor and Section Chief
    Baylor College of Medicine

    Disclosure:
    • Research Support: Genentech/Roche
    • Consultancy: Boehringer; Bristol Meyers Squibb; Genentech/Roche

Program Director

  1. Richard J. Hamill, M.D.

    Richard J. Hamill, M.D.

    Professor
    Baylor College of Medicine

    Disclosure:

    Nothing to disclose.

Planning Committee Members

  1. Stephen B. Greenberg, M.D.

    Stephen B. Greenberg, M.D.

    Distinguished Service Professor
    Baylor College of Medicine

    Disclosure:

    Nothing to disclose.

  2. Richard J. Hamill, M.D.

    Richard J. Hamill, M.D.

    Professor
    Baylor College of Medicine

    Disclosure:

    Nothing to disclose.

  3. Erica Lescinskas, M.D.

    Erica Lescinskas, M.D.

    Assistant Professor
    Baylor College of Medicine

    Disclosure:

    Nothing to disclose.

  4. Zaven Sargsayan, M.D.

    Zaven Sargsayan, M.D.

    Assistant Professor
    Baylor College of Medicine and Ben Taub Hospital

    Disclosure:

    Nothing to disclose.

  5. Chirayu Shah, M.D., M.Ed.

    Chirayu Shah, M.D., M.Ed.

    Associate Professor
    Baylor College of Medicine

    Disclosure:

    Nothing to disclose.

  6. Stephanie Sherman, M.D.

    Stephanie Sherman, M.D.

    Assistant Professor
    Baylor College of Medicine

    Disclosure:

    Nothing to disclose.

Contributor

  1. Ivan Rosas, M.D.

    Ivan Rosas, M.D.

    Professor and Section Chief
    Baylor College of Medicine

    Disclosure:
    • Research Support: Genentech/Roche
    • Consultancy: Boehringer; Bristol Meyers Squibb; Genentech/Roche